assist clinical trial | assisting clinical trials | assist in clinical trials | assisting clinical trial

non-clinical study | preclinical study | pre-clinical study | preclinical test | pre-clinical test | pre-clinical testing | preclinical trial | pre-clinical trial

multicenter trial | multicentre trial | multicenter clinical trial | multicentre clinical trial | multicentered trial | multicentered clinical trial | multicenter study | multicentre study | multicenter clinical study | multicentre clinical study | multicentered study | multicentered clinical study

EU Database on Clinical Trials | European Clinical Trials Database | EudraCT [Abbr.]

comparative clinical trial | controlled clinical trial | CCT [Abbr.]

apply good clinical trial practice | meet good clinical practice standards | apply good clinical practice | apply good clinical practices

controlled trial | controlled clinical trial | comparative trial | comparison trial | controlled study | comparative study | comparison study | controlled clinical study

Clinical Trial Program [ Clinical Trials Program ]

animal trials | development phases for pharmaceutical drugs | clinical phase | pharmaceutical drug development

We very much welcome the pilot program launched by the Canadian Institutes of Health Research to create a national clinical trial agreement.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Can ...[+++]adian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

Yesterday, The New York Times gave kudos to the “test and treat” pilot program pioneered by Dr. Julio Montaner, head of the HIV-AIDS clinical trials at St. Paul's Hospital.

This pilot project, known as the European and Developing Countries Clinical Trials Partnership, received an equivalent contribution (€200 million) from the European countries participating and concentrates on developing new medicines, vaccines and microbicides effective against the three diseases in question and stepping up clinic research capacity in the sub-Saharan African countries.